Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-04-11 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
第三届监事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 24th meeting of the third Supervisory Board of the company. It details the meeting attendance, the approval of stock incentive plans, and the voting results. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement of board/management decisions related to stock incentive plans. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2019-04-11 Chinese
关于2017年股票期权激励计划首次授予股票期权第一个行权期可行权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the first exercise period of a 2017 stock option incentive plan by the company 健帆生物科技集团股份有限公司. It includes specifics about the number of stock options exercisable, the exercise price, the conditions met for exercising, approvals by the board and supervisory committee, legal opinions, and financial impact analysis. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not a call transcript, earnings release, or a general regulatory filing. The content focuses on the stock option plan exercise event, which is a capital/financing activity related to the company's equity structure and employee incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8033 characters) and detailed content confirm it is a substantive update, not a brief notice or certification.
2019-04-11 Chinese
独立董事关于公司第三届董事会第三十三次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on specific company matters related to stock incentive plans and stock option exercises. It references compliance with regulatory guidelines and company rules, and provides an independent opinion on the legitimacy and legality of stock incentive plan executions. The document is relatively short (1112 characters) and does not contain financial statements or comprehensive financial data. It is not an annual report, audit report, or earnings release. It is also not a meeting presentation or voting result announcement. The content is a formal opinion related to governance and compliance matters, specifically about stock incentive plans and their execution. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement and does not constitute a full report or financial statement.
2019-04-11 Chinese
国浩律师（深圳）事务所关于公司2016年限制性股票激励计划首次授予部分第二个解除限售期解除限售条件成就之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the fulfillment of conditions for the second unlocking period of a 2016 restricted stock incentive plan for a company. It details the legal compliance, procedures followed, and conditions met for the stock incentive plan's unlocking. The document is not a financial report, earnings release, or management discussion, but a legal certification related to a stock incentive plan. It does not announce voting results, changes in management, or capital structure changes. It is a standalone legal opinion on a specific corporate action related to stock incentives. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance/legal document that does not fit other specific categories.
2019-04-11 Chinese
第三届董事会第三十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 33rd meeting of the 3rd Board of Directors of the company. It details the meeting date, attendance, voting results, and decisions regarding stock incentive plans. It includes references to independent opinions and legal reviews but does not contain financial statements or detailed financial performance data. The content focuses on board decisions and governance matters related to stock incentives. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-04-11 Chinese
上海荣正投资咨询股份有限公司关于公司2017年股票期权激励计划首次授予股票期权第一个行权期行权条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the achievement of exercise conditions for the first exercise period of a 2017 stock option incentive plan by the company 健帆生物科技集团股份有限公司. It includes detailed explanations of the stock option plan, approval procedures, performance conditions, and verification opinions by the financial advisor. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a standalone advisory report focused on the stock option incentive plan and its conditions, which fits the category of Audit Report / Information (AR) as it involves verification and opinion on compliance and conditions related to the incentive plan. The length (6783 characters) and content confirm it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2018
2019-04-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.